Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov30410.25208/0042-4609-2017-93-2-20-26SHORT COMMUNICATIONКРАТКИЕ СООБЩЕНИЯAssessment of prognostic predictive value at the mycosis fungoidesОценка прогностической значимости маркеров грибовидного микозаZhukovA. S.ЖуковА. С.
Russian Federation
md.zhukov@gmail.comTelichkoI. N.ТеличкоИ. Н.
Russian Federation
BelousovaI. E.БелоусоваИ. Э.
Russian Federation
SamcovA. V.СамцовА. В.
Russian Federation
Military Medical Academy named after S. M. Kirov Ministry of Defense of the Russian FederationФГБВОУ ВО «Военно-медицинская академия им. С. М. Кирова» МО РФDermatovenerologic dispensary No. 4СПб ГБУЗ «Кожно-венерологический диспансер № 4»24042017932202624082017Copyright ©; 2017, Zhukov A.S., Telichko I.N., Belousova I.E., Samcov A.V.Copyright ©; 2017, Жуков А.С., Теличко И.Н., Белоусова И.Э., Самцов А.В.2017Zhukov A.S., Telichko I.N., Belousova I.E., Samcov A.V.Жуков А.С., Теличко И.Н., Белоусова И.Э., Самцов А.В.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/304

Micosis fungoides is a primary skin lymphoma characterized with indolent disease course and favorable prognosis. Опіу at some patients one can observe aggressive development of the disease to malignant stage with the exracutaneous outspread. the modern data about the prognostic factors are presented in the review. Disclosure of these factors allows to forecast the course of disease. there is given attention to integral estimation of survival rates on the ground of tNMB-staging sand estimation of the CUP-index. Definition of combination of different prognostic factors would allow to create prognostic models enabling to diagnose on the early stages of disease the patients with high risk of progression of mycosis fungoides.

Грибовидный микоз - первичная лимфома кожи, характеризующаяся индолентным течением и благоприятным прогнозом, и только у небольшой части пациентов наблюдается агрессивное развитие с переходом в опухолевую стадию и внекожным распространением процесса. В обзоре представлены современные сведения о прогностических факторах, обнаружение которых позволит предсказать течение заболевания. Уделено внимание суммарной оценке показателей выживаемости на основании проведения TNMB-стадирования и расчета CLIP-индекса. Определение комбинации различных прогностических факторов позволит создать прогностические модели и на их основе выявлять пациентов с высоким риском прогрессии грибовидного микоза на ранних стадиях заболевания.

грибовидный микозпрогнозпрогностические маркерывыживаемостьриск прогрессииmycosis fungoidesprognosisprognostic markerssurvival ratesrisk of disease progressionQuaglino P., Pimpinelli N., Berti E., Calzavara-Pinton P., Alfonso Lombardo G., Rupoli S., Alaibac M., Bottoni Ü., Carbone A., Fava P., Fimiani M., Mamusa A. M., Titli S., Zinzani P. L., Bernengo M. G.; Gruppo Italiano Linfomi Cutanei. Time course, clinical pathways, and longterm hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012 Dec 1; 118 (23): 5830-9Vonderheid E. C., Pavlov I., Delgado J. C., Martins T. B., Telang G. Fl., Hess A. D., Kadin M. E. Prognostic factors and risk stratification in early mycosis fungoides. Leuk Lymphoma 2014 Jan; 55 (1): 44-50.Willemze R., Jaffe E. S., Burg G., Cerroni L., Berti E., Swerdlow S. H., Ralfkiaer E., Chimenti S., Diaz-Perez J. L., Duncan LM, Grange F., Harris N. L., Kempf W., Kerl H., Kurrer M., Knobler R., Pimpinelli N., Sander C., Santucci M., Sterry W., Vermeer M. H., Wechsler J., Whittaker S., Meijer C. J. WHO-EORTC classification for cutaneouslymphomas. Blood 2005 May 15; 105 (10): 3768-85.Zackheim H. S., Amin S., Kashani-Sabet M., McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am AcadDermatol 1999 Mar; 40 (3): 418-25.Elliott B., Scolyer R. A., Suciu S., Lebecque S., Rimoldi D., Gugerli O. et al. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 2007; 13: 3825-3830.Jovanovich M. P., Jakovich L., Bogdanovich A., Markovich O., Martinovich V. C., Mihaljevich B. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki-67-positive tumor cells. VojnosanitPregl 2009 Sep; 66 (9): 738-43.Agar N. S., Wedgeworth E., Crichton S. et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: Validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J ClinOncol 2010; 28: 4730-4739.Sun G., Berthelot C., Li Y., Glass D. A. 2nd, George D., Pandya A., Kurzrock R., Duvic M. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am AcadDermatol 2009 Feb; 60 (2): 231-5.Talpur R., Singh L., Daulat S., Liu P., Seyfer S., Trynosky T. et al. Long-term outcomes of 1,263 patients with mycosis fungoides and S ezary syndrome from 1982 to 2009. ClinCancerRes 2012; 18: 5051-60.Kim Y. H., Liu H. L., Mraz-Gernhard S., Varghese A., Hoppe R. T. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003 Jul; 139 (7): 857-66.Diamandidou E., Colome M., Fayad L., Duvic M., Kurzrock R. Prognostic factor analysis in mycosis fungoides/S ezary syndrome. J Am AcadDermatol 1999; 40: 914-24.Diamandidou E., Colome-Grimmer M., Fayad L., Duvic M., Kurzrock R. Transformation of mycosis fungoides/S ezary syndrome: clinical characteristics and prognosis. Blood 1998; 92: 1150-9.Meissner K., Loning T., Rehpenning W. Epidermal Langerinerhans cells and prognosis of patients with mycosis fungoides and Se'zary syndrome. In Vivo 1993; 7: 277-280.Goteri G., Filosa A., Mannello B., Stramazzotti D., Rupoli S., Leoni P., fabris G. Density of neoplastic lymphoid infiltrate, CD8+ T cells, and CD1a+ dendritic cells in mycosis fungoides. J ClinPathol 2003 Jun; 56 (6): 453-8.Schlapbach C., Ochsenbein A., Kaelin Ü., Hassan A. S., Hunger R. E., Yawalkar N. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol 2010 Jun; 62 (6): 995-1004.Schwingshackl P., Obermoser G., Nguyen V. A., Fritsch P., Sepp N., Romani N. Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. ActaDermVe-nereol 2012 May; 92 (3): 269-75.Zhukov A. S., Belousova I. E., Khairutdinov V. R., Samtsov A. V. Rol’ langerinpozitivnih i CD83+ kletok v patogeneze gribovidnogo mikoza. Vestn dermatol venerol 2013; (4): 38-43.Zhukov A. S., Belousova I. E., Samtsov A. V. Foxp3+ T-lymphocytes in the pathogenesis of mycosis fungoides. Vestn dermatol venerol 2014; 5: 68-72.Gjerdrum L. M., Woetmann A., Odum N., Burton C. M., Rossen K., Skovgaard G. L., Ryder L. P., Ralfkiaer E. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007 Dec; 21 (12): 2512-8.Fried I., Cerroni L. FOXP3 in sequential biopsies of progressive mycosis fungoides. Am J Dermatopathol 2012 May; 34 (3): 263-5.Olsen E. A., Whittaker S., Kim Y. H., Duvic M., Prince H. M., Lessin S. R. et al. Clinical end points and response criteria in mycosis fungoides and S ezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the Ünited States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J ClinOncol 2011; 29: 2598-607.Zhukov A. S., Belousova I. E., Khairutdinov V. R., Telichko I. N., Samtsov A. V. Level of the proliferative activity of lymphocytes in case of mycosis fungoides and plaque parapsoriasis. Vestn dermatol venerol 2014; 1:30-36.Jankowska-Konsur A., Kobierzycki C., Reich A., Grzegrzolka J., Maj J., Dziegiel P. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas. Anticancer Res 2015 Nov; 35 (11): 6017-26.Tobisawa S., Honma M., Ishida-Yamamoto A., Saijo Y., Iizuka H. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor. J Dermatol Sci 2013 Sep; 71 (3): 160-6.Eklund Y., Aronsson A., Schmidtchen A., Relander T. Mycosis Fungoides: A Retrospective Study of 44 Swedish Cases. ActaDermVenereol 2016 Jun 15; 96 (5): 669-73.Zhukov A. S., Belousova I. E., Samtsov A. V. Immunological and molecular genetic mechanisms of the development of mycosis fungoides. Vestn dermatol venerol 2015; 4: 42-50.Fraser-Andrews E. A., Woolford A. J., Russell-Jones R., Seed P., Whittaker S. J. Detection of a peripheral blood T cell clone an independent prognostic marker in mycosis fungoides J Invest Dermatol 2000; 114: 117-21.Litvinov I. V., Kupper T. S., Sasseville D. Exp-Dermatol. The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression 2012 Dec; 21 (12): 964-6.Laharanne E., Chevret E., Idrissi Y. et al. CDK-N2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol 2010; 23; 547-558.Shin J., Monti S., Aires D. J., et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007; 110: 3015-3027.Salgado R., Servitje O., Gallardo F., et al. Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol 2010; 130: 1126-1135.Lin W. M., Lewis J. M., Filler R. B., Modi B. G., Carlson K. R., Reddy S., Thornberg A., Saksena G., Umlauf S., Oberholzer P. A., Karpova M., Getz G., Mane S., Garraway L. A., Dummer R., Berger C. L., Edelson R. L., Girardi M. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. J InvestDermatol 2012 Jan; 132 (1): 188-97.Wilcox R. A. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014 Aug; 89 (8): 837-51.Olsen E., Vonderheid E., Pimpinelli N. et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.Russian clinical guidelines for diagnosis and treatment of lymphoproliferative diseases. Eds.: prof. Poddubnaya I. V., prof. Savchenko V. G. M: MMA MediaMedica 2014; 128.Benton E. C., Crichton S., Talpur R. et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides Sezary syndrome. Eur J Cancer 2013; 49; 2859-2868.Zhukov A. S., Belousova I. E., Samtsov A. V. Immunohistochemistry method and diagnostics of mycosis fungoides. Vestn dermatol venerol 2014; 2: 38-46.